We are live on ! Find out more
AGRX

Agile Therapeutics
AGRX

Delisted

AGRX was delisted on the 25th of March, 2024.

Back to rankings

48 hedge funds and large institutions have $151M invested in Agile Therapeutics in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 20 increasing their positions, 2 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 2

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

7% more funds holding

Funds holding: 45 → 48 (+3)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

7% less capital invested

Capital invested by funds: $161M → $151M (-$10.6M)

Holders
48
Holders Change
+3
Holders Change %
+6.67%
% of All Funds
1.28%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.11%
New
11
Increased
20
Reduced
2
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Caxton Corporation
New Jersey
+$9.06M
2
Franklin Resources
Franklin Resources
California
+$9.04M
3
RCM
RA Capital Management
Massachusetts
+$6.87M
4
PAI
ProQuest Associates IV
Florida
+$2.54M
5
CAM
Cormorant Asset Management
Massachusetts
+$2.43M

Top Sellers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
-$2.93M
2
Marshall Wace
Marshall Wace
United Kingdom
-$1.27M
3
HCMT
Highland Capital Management (Texas)
Texas
-$980K
4
Citadel Advisors
Citadel Advisors
Florida
-$106K
5
GIM
Granahan Investment Management
Massachusetts
-$90.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
PWMAG
26
Pinnacle Wealth Management Advisory Group
New Jersey
$484K +$194K +15 +63%
BCM
27
Bridgeway Capital Management
Texas
$418K – – –
FLAM
28
First Light Asset Management
Minnesota
$382K +$400K +31 New
Bank of New York Mellon
29
Bank of New York Mellon
New York
$355K +$103K +8 +38%
BIM
30
BlackRock Investment Management
Delaware
$258K +$38.7K +3 +17%
TCIM
31
TIAA CREF Investment Management
New York
$202K – – –
California State Teachers Retirement System (CalSTRS)
32
California State Teachers Retirement System (CalSTRS)
California
$181K +$64.6K +5 +50%
RHJA
33
Rice Hall James & Associates
California
$158K – – –
TA
34
Teachers Advisors
New York
$93K – – –
Charles Schwab
35
Charles Schwab
California
$84K – – –
William Blair & Company
36
William Blair & Company
Illinois
$68K +$77.5K +6 New
SIM
37
Spark Investment Management
New York
$64K +$64.6K +5 New
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$58K – – –
Citigroup
39
Citigroup
New York
$58K +$64.6K +5 New
NFA
40
Nationwide Fund Advisors
Ohio
$57K – – –
Wells Fargo
41
Wells Fargo
California
$41K +$12.9K +1 +50%
AIG
42
American International Group
New York
$38K – – –
Royal Bank of Canada
43
Royal Bank of Canada
Ontario, Canada
$30K – – –
Morgan Stanley
44
Morgan Stanley
New York
$29K – – –
BA
45
BlackRock Advisors
Delaware
$28K +$12.9K +1 +100%
Manulife (Manufacturers Life Insurance)
46
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$16K +$12.9K +1 New
Deutsche Bank
47
Deutsche Bank
Germany
$12K – – –
UBS Group
48
UBS Group
Switzerland
$6K -$25.8K -2 Closed
JP Morgan Chase
49
JP Morgan Chase
New York
$6K – – –
MFS
50
MSI Financial Services
Massachusetts
$3K -$12.9K -1 Closed
1
2
3

AGRX Hedge Fund Activity: Q1 2016 in Review

48 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2016, worth a combined $151M — down 6.5% from $161M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new AGRX positions and 8 closed out — a net gain of 3 holders — while 20 added to existing stakes and 2 trimmed.

The largest buyer was Caxton Corporation, adding an estimated $9.06M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.93M sold.

  • 48 institutional investors held Agile Therapeutics (AGRX) as of Q1 2016, up from 45 in Q4 2015.
  • Funds reported $151M of Agile Therapeutics stock for Q1 2016, down 6.5% quarter-over-quarter.
  • 11 funds opened new Agile Therapeutics positions in Q1 2016 and 8 closed out, a net change of +3 holders.
  • The largest Agile Therapeutics buyer in Q1 2016 was Caxton Corporation, an estimated $9.06M added.
  • The largest Agile Therapeutics seller in Q1 2016 was Opaleye Management, an estimated $2.93M sold.

Based on aggregated 13F filings for Q1 2016.